Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Antiangiogenic therapy in breast cancer

Antiangiogenic therapy in breast cancer Based on a strong rationale for anti-VEGF (vascular endothelial growth factor) treatment in breast cancer and promising preclinical data, great hopes have been placed on the anti-VEGF antibody bevacizumab. Clinical trials, however, reported conflicting results. In metastatic human epidermal growth factor receptor 2(HER2)-negative breast cancer, the addition of bevacizumab to standard chemotherapy improved consistently progression-free survival (PFS), however, without effect on overall survival (OS). In early breast cancer bevacizumab increased the pathologic complete response rate (pCR) after neoadjuvant therapy, but adjuvant trials did not demonstrate an effect on long-term survival. Unfortunately, despite extensive research, there is still no biomarker for bevacizumab efficacy available, making patient selection difficult. This review summarizes all phase III trials investigating efficacy and toxicity of bevacizumab in early, locally advanced and metastatic breast cancer. It recapitulates the main toxicities, gives an overview on biomarker studies and discusses the role and future aspects of antiangiogenic therapy in breast cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Antiangiogenic therapy in breast cancer

Download PDF
8 pages

Loading next page...
 
/lp/springer-journals/antiangiogenic-therapy-in-breast-cancer-sYNbXU0ca1
Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0362-0
Publisher site
See Article on Publisher Site

Abstract

Based on a strong rationale for anti-VEGF (vascular endothelial growth factor) treatment in breast cancer and promising preclinical data, great hopes have been placed on the anti-VEGF antibody bevacizumab. Clinical trials, however, reported conflicting results. In metastatic human epidermal growth factor receptor 2(HER2)-negative breast cancer, the addition of bevacizumab to standard chemotherapy improved consistently progression-free survival (PFS), however, without effect on overall survival (OS). In early breast cancer bevacizumab increased the pathologic complete response rate (pCR) after neoadjuvant therapy, but adjuvant trials did not demonstrate an effect on long-term survival. Unfortunately, despite extensive research, there is still no biomarker for bevacizumab efficacy available, making patient selection difficult. This review summarizes all phase III trials investigating efficacy and toxicity of bevacizumab in early, locally advanced and metastatic breast cancer. It recapitulates the main toxicities, gives an overview on biomarker studies and discusses the role and future aspects of antiangiogenic therapy in breast cancer.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Nov 6, 2017

References

  • Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis
    Bos, R
  • Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis
    Uzzan, B
  • Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment
    Linderholm, B
  • Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma
    Linderholm, B
  • First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study
    Bergh, J
  • RESILIENCE: phase III randomized, double-blind trial comparing Sorafenib with Capecitabine versus placebo with Capecitabine in locally advanced or metastatic HER2-negative breast cancer
    Baselga, J
  • Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
    Miller, K
  • Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2‑negative metastatic breast cancer
    Miles, DW
  • RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2‑negative, locally recurrent or metastatic breast cancer
    Robert, NJ
  • First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients
    Miles, DW
  • Bevacizumab and breast cancer: a meta-analysis of first-line phase III studies and a critical reappraisal of available evidence
    Rossari, JR
  • AVEREL: a randomized phase III trial evaluating Bevacizumab in combination with Docetaxel and Trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer
    Gianni, L
  • Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer
    Preusser, M
  • Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial
    Zielinski, C
  • First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients
    Smith, IE
  • Phase III trial evaluating Letrozole as first-line endocrine therapy with or without Bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer: CALGB 40503 (alliance)
    Dickler, MN
  • Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study
    Martin, M
  • RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2‑negative metastatic breast cancer
    Brufsky, AM
  • Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial
    Minckwitz, G
  • Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
    Vrdoljak, E
  • Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial
    Gligorov, J
  • A real-world multicentre retrospective study of Paclitaxel-Bevacizumab and maintenance therapy as first-line for HER2-negative metastatic breast cancer
    Gamucci, T
  • Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
    Gerber, B
  • Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)dagger
    Minckwitz, G
  • Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B‑40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial
    Bear, HD
  • Bevacizumab added to neoadjuvant chemotherapy for breast cancer
    Bear, HD
  • Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
    Earl, HM
  • Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial
    Earl, HM
  • Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study
    Bertucci, F
  • Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
    Bell, R
  • Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
    Cameron, D
  • E5103 A double-blind phase III trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or placebo in patients with lymph node positive and high risk lymph node negative breast cancer
    Miller, K
  • Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer
    Slamon, DJ
  • Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies
    Hurwitz, HI
  • Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): a double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
    Miles, D
  • Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
    Miles, DW
  • Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer
    Jubb, AM
  • Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial
    Cutsem, E
  • Tumor tissue based biomarker analysis in NO16966: a randomized phase III study of first-line bevacizumab in combination with oxaliplatin-based chemotherapy in patients with mCRC
    Foernzler, D
  • Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
    Schneider, BP
  • Analysis of early hypertension and clinical outcome with Bevacizumab: results from seven phase III studies
    Hurwitz, HI
  • Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis
    Gampenrieder, SP
  • VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T‑cell proliferation in colorectal cancer
    Terme, M
  • VEGF as a mediator of tumor-associated immunodeficiency
    Ohm, JE; Carbone, DP
  • Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells
    Oyama, T
  • Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines
    Farsaci, B
  • Bevacizumab plus ipilimumab in patients with metastatic melanoma
    Hodi, FS
  • The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
    Osada, T
  • Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
    Miller, KD